CoreCap Advisors’s Alzamend Neuro ALZN Stock Holding History

CoreCap Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-79	Closed	-$1.2K	–	2856
2024 Q3	$1.2K	Hold	79	–	–	﹤0.01%	2243
2024 Q2	$2.79K	Buy	+79	New	+$4.52K	﹤0.01%	1261

Other funds holding ALZN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CoreCap Advisors's ALZN Position: Q4 2024 in Review

CoreCap Advisors sold out of Alzamend Neuro (ALZN) in Q4 2024, closing a stake of 79 shares — an estimated $1.2K sold.

CoreCap Advisors first reported a position in ALZN in Q2 2024 and held it in 2 quarters. The position peaked at $2.79K in Q2 2024. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2024.

CoreCap Advisors reported no remaining Alzamend Neuro position as of Q4 2024 after selling out during the quarter.
CoreCap Advisors sold 79 Alzamend Neuro shares in Q4 2024, an estimated $1.2K.
CoreCap Advisors first reported a position in Alzamend Neuro in Q2 2024 and held it in 2 quarters.
CoreCap Advisors's Alzamend Neuro position peaked at $2.79K in Q2 2024.
14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2024.

Based on CoreCap Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.